The lede:

Under intense criticism for its slow response to drug and device safety problems, the Food and Drug Administration last month announced a new initiative to detect adverse event patterns and warn physicians earlier.

The effort, known as the Sentinel Initiative, marks a significant shift from relying on physicians and patients to report adverse events toward a program of high-tech, active postmarket surveillance.

The whole shebang.